TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03323736

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Iontophoresis & tube placement
Description: Subjects will receive active Tymbion iontophoresis and will have tubes placed in-office using the Tube Delivery System in all ears indicated for tube placement.

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Iontophoresis & tube placement
Description: Subjects will receive active Tymbion iontophoresis and will have tubes placed in-office using the Tube Delivery System in all ears indicated for tube placement.

Intervention type: DEVICE
Group type: OTHER
Intervention: Tube placement
Description: Subjects will have tubes placed in the OR using the Tube Delivery System in all ears indicated for tube placement.
Study: NCT00649831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin/clavulinic acid
Description: amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
Study: NCT01650740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30 mg daily x 1 week followed by 60 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study visits only
Description: Weekly visits x 4 weeks followed by visits every 2 weeks
Study: NCT01912690

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: aerobic and strength training
Study: NCT00471887

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CP-675,206
Description: Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
Study: NCT04437992

Intervention type: GENETIC
Intervention: NIPT
Description: The test, which requires two 10 ml tubes of blood, will be performed simultaneously with the chemical biomarkers of the combined test at 10-12 weeks of gestation
Study: NCT02442258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: A single dose of ABT-493 will be given orally in combination with ABT-530.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: A single dose of ABT-493 will be given orally in combination with ABT-530.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: A single dose of ABT-493 will be given orally in combination with ABT-530.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: A single dose of ABT-493 will be given orally in combination with ABT-530.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: A single dose of ABT-493 will be given orally in combination with ABT-530.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: A single dose of ABT-493 will be given orally in combination with ABT-530.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: A single dose of ABT-530 will be given orally in combination with ABT-493.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: A single dose of ABT-530 will be given orally in combination with ABT-493.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: A single dose of ABT-530 will be given orally in combination with ABT-493.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: A single dose of ABT-530 will be given orally in combination with ABT-493.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: A single dose of ABT-530 will be given orally in combination with ABT-493.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-530
Description: A single dose of ABT-530 will be given orally in combination with ABT-493.
Study: NCT00006094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: external beam radiation therapy
Description: Undergo external beam radiation therapy
Study: NCT04870541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: Patients receiving 8 mg of ondansetron diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater(75 patients).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nefopam Injectable Solution
Description: Patients receiving 20 mg of nefopam diluted in 20 ml of 0.9% normal saline over 30 minutes as they arrive to the operating theater (75 patients)
Study: NCT03330184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine Hydrochloride group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bifidobacterium group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine Hydrochloride and Bifidobacterium group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03951909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy activity and awareness intervention: PAAI
Description: 10 to 12 persons will be invited to each group. The intervention will consist on 8 weekly sessions including the same key elements each time: introduction with a mindfulness exercise and a ball game, several movements while sitting on a chair, standing proprioceptive exercises with wooden sticks and exercises to raise awareness of muscle tensions in the body, active movements stimulating the balance, coordination and breathing and finally relaxation and a short closing round.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy activity and awareness intervention: PAAI
Description: 10 to 12 persons will be invited to each group. The intervention will consist on 8 weekly sessions including the same key elements each time: introduction with a mindfulness exercise and a ball game, several movements while sitting on a chair, standing proprioceptive exercises with wooden sticks and exercises to raise awareness of muscle tensions in the body, active movements stimulating the balance, coordination and breathing and finally relaxation and a short closing round.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological intervention: Teaching recovery techniques (TRT)
Description: TRT is composed of five two-hour group teaching sessions with up to 15 participants. The first two sessions deal with intrusive thoughts and feelings: problems such as bad memories, nightmares, and flashbacks. The third session deals with arousal, coming to the surface as difficulties in relaxing, concentrating and sleeping. The fourth and fifth sessions deal with avoidance: ones fears, and difficulties in facing up to reminders of the war and violence.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological intervention: Teaching recovery techniques (TRT)
Description: TRT is composed of five two-hour group teaching sessions with up to 15 participants. The first two sessions deal with intrusive thoughts and feelings: problems such as bad memories, nightmares, and flashbacks. The third session deals with arousal, coming to the surface as difficulties in relaxing, concentrating and sleeping. The fourth and fifth sessions deal with avoidance: ones fears, and difficulties in facing up to reminders of the war and violence.
Study: NCT01936493

Intervention type: GENETIC
Intervention: DNA analysis
Description: At a future time DNA analysis will be performed

Intervention type: OTHER
Intervention: Hormonal analysis
Description: Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.
Study: NCT05455801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: negative preassure wound therapy
Description: wound treated with negative pressure therapy dressing
Study: NCT02606357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INSULIN GLARGINE
Description: Pharmaceutical form:Solution~Route of administration: Subcutaneous
Study: NCT01308229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nile PAX® paclitaxel-eluting coronary stent
Description: Implantation of a Nile PAX bifurcation dedicated drug-eluting stent in coronary arteries to treat stenosis lesions
Study: NCT00785343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reo Go robotic arm trainer
Description: Robotic training with the Reo Go is included with conventional treatment during daily OT sessions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Occupational therapy that is the current standard of care
Study: NCT03013049

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non cultured epidermal cell suspension
Description: Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non cultured epidermal cell suspension
Description: Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non cultured dermal cell suspension
Description: Non-cultured Dermal Cell Suspension Skin punch will be collected in phosphate buffer saline (PBS) with antibiotics (penicillin and streptomycin). The epidermis will be cut off from dermis carefully using a surgical blade (Epidermal part will be used for the epidermal cell suspension). Dermis will be then cut into small pieces and incubated in collagenase (1mg/ml) overnight at room temperature. Next day content will be diluted with PBS and centrifuged at 1000rpm for 5 minutes. Pellet will be washed three times with PBS to remove collagenase activity. Phosphate buffer saline is added to make suspension of non-cultured dermal cells and will be used for the autologous transplantation.
Study: NCT04673916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Healing evaluation
Description: Treatments were topically applied for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Healing evaluation
Description: Treatments were topically applied for 5 days
Study: NCT01522261

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical Bowel Prep
Description: Patients randomized to MBP will complete procedure per standard instructions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Mechanical Bowel Prep
Description: Patient randomized to fleets enemas only prior to surgery
Study: NCT00007020

Intervention type: DRUG
Group type: OTHER
Intervention: Cholic Acids
Description: 10-15 mg/kg body weight/day taken orally.
Study: NCT00999960

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Radical Prostatectomy (without a simulator)
Description: without simulator

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Radical Prostatectomy (with a simulator)
Description: Learning with a simulator
Study: NCT04058548

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sit to stand test
Description: Participants will complete a sit to stand test in addition to a 6 minute walk test
Study: NCT01073917

Intervention type: OTHER
Group type: OTHER
Intervention: Spontaneous Breathing

Intervention type: OTHER
Group type: OTHER
Intervention: Pressure Controlled Ventilation

Intervention type: OTHER
Group type: OTHER
Intervention: Pressure Support Ventilation
Study: NCT00167388

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: feed during blood transfusion
Description: babies receiving the intervention are fed during the PRBC transfusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: feed during blood transfusion
Description: babies receiving the intervention are fed during the PRBC transfusion
Study: NCT01113346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filtrum-STI (lignin hydrolytic)
Description: For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.~For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.~For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days.
Study: NCT02881619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac
Description: The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will receive a single-dose of placebo one hour before the bleaching procedure.
Study: NCT04214639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-126 Gel
Description: IDP-126 Gel applied topically to the face once daily for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-126 Vehicle Gel
Description: IDP-126 Vehicle Gel applied topically to the face once daily for 12 weeks.
Study: NCT00185601

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet Diabetes Self-Management Program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Diabetes Self-Management Program
Study: NCT01756118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Description: A minimum of 3 dose levels
Study: NCT00687102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen
Description: oral tamoxifen plus placebo daily for 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: raloxifene
Description: oral raloxifene plus placebo daily for 5 years
Study: NCT00734071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate-release tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vortioxetine placebo-matching capsules
Study: NCT00843154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan and standard chronic heart disease therapy
Description: Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard chronic heart disease therapy
Description: Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
Study: NCT01088854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: unique session of 30-minute of continuous airway positive pressure
Study: NCT02886871

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Step Goal Delivery by Smartphone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Goal Delivery by Smartphone
Study: NCT01989611

Intervention type: DRUG
Group type: OTHER
Intervention: emtricitabine / tenofovir 200/300 mg
Description: Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
Study: NCT01934309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TB reminders
Description: The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-speciﬁc clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
Study: NCT03864913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone injection
Description: SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone injection
Description: SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.
Study: NCT03495999

Intervention type: DIAGNOSTIC_TEST
Intervention: hyperuricemia
Description: serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women

Intervention type: DIAGNOSTIC_TEST
Intervention: hyperuricemia
Description: serum uric acid of 7mg/dl or more in men or 6mg/dl or more in women
Study: NCT03864913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone injection
Description: SQ or IM testosterone injections for pubertal induction of transgender male adolescents. Increasing doses per protocol at 3 month and 6 month follow up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PedsQL questionnarie
Description: Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.
Study: NCT00625859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK189075
Description: GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.
Study: NCT03864913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PedsQL questionnarie
Description: Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PedsQL questionnarie
Description: Validated Pediatric Quality of Life questionnaire completed by subjects at baseline, 3 month and 6 month study visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masculinizing effects questionnaire
Description: Subjects complete self-reported questionnaire at 3 month and 6 month study visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masculinizing effects questionnaire
Description: Subjects complete self-reported questionnaire at 3 month and 6 month study visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Masculinizing effects questionnaire
Description: Subjects complete self-reported questionnaire at 3 month and 6 month study visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication experience questionnaire
Description: Subjects complete self-reported questionnaire at 3 month and 6 month study visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication experience questionnaire
Description: Subjects complete self-reported questionnaire at 3 month and 6 month study visits.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication experience questionnaire
Description: Subjects complete self-reported questionnaire at 3 month and 6 month study visits.
Study: NCT04387266

Intervention type: RADIATION
Intervention: modified reduce-volume target IMRT
Description: The gross tumor volume of the nasopharynx and neck nodes (GTVnx and GTVnd) were delineated according to the tumor extension. The CTVnx was defined as GTVnx + nasopharynx mucosa + 8mm +corresponding anatomical structure without the delineation of CTV1. The CTVnd was defined as GTVnd plus the elective neck area. The prescribe doses of GTVnx/GTVnd, CTVnx, CTVnd were 66-70Gy,54-56Gy and 50-54Gy in 31-35 fractions, respectively.
Study: NCT00963924

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: 40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.